Navigation Links
Monogram Announces Third Quarter 2007 Financial Results
Date:10/24/2007

venues, especially during the first two quarters of 2006, included substantial revenues from the use of the Company's assays in Pfizer's phase III trial of maraviroc.

The net loss was $18.5 million, or $0.14 per common share, in the first nine months of 2007, compared to a net loss of $31.7 million, or $0.24 per common share, for the same period in 2006. Included in these results were substantial non-cash items, which are described below under "Non-GAAP Proforma Results." On a non-GAAP proforma basis, adjusted for these non-cash items, the net loss was $25.6 million, or $0.19 per share, in the first nine months of 2007 compared to a net loss of $15.3 million, or $0.12 per share, in the same period of 2006.

The Company had approximately $30 million in cash resources (comprised of cash, cash equivalents and short-term investments) at September 30, 2007.

Monogram's Trofile Assay and Pfizer's maraviroc

"This has been a pivotal quarter for our HIV business," said William Young, Monogram chief executive officer. "Several positive developments, including FDA approval of Pfizer's maraviroc, culminated in the commercial introduction of Trofile and the rapid establishment of coverage and reimbursement by Medicare. This important reimbursement benchmark bodes well for ongoing discussions with other public and private payers."

Pfizer has announced several positive developments for maraviroc, know as Selzentry(TM) in the U.S. and Celsentri(R), outside of the U.S. These include:

-- positive clinical results from 48 week follow up of patients enrolled

in both the phase III trial of maraviroc in treatment-experienced

patients and the separate trial in treatment-naive patients

-- approval, by both the FDA and the European Commission (EC), of

maraviroc for use in treatment-experienced patients selected by tropism

testing

-- availability, in mid September, of maraviroc throughout the U.S.

Monog
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 22, 2014 Ophthalmic drug delivery ... and challenging endeavors as the anatomy, physiology and ... to the foreign substances. Ocular drug delivery technologies ... medication and minimal use of needles; also it ... and provides specific targeting within the ocular globe. ...
(Date:8/22/2014)... Los Angeles (PRWEB) August 22, 2014 ... for age-defying products, is in the spotlight again. ... night cream and its NeriumFirmTM Body Contouring Cream ... presented by Backstage Creations during the 66th Primetime ... the patented NAE-8® extract, third-party clinical trials show ...
(Date:8/21/2014)... Finnish-Swedish research group at the Institute for Molecular ... institutet, Stockholm, has developed a novel "man and ... This innovative diagnostic aid was described in ... The method is based on computer vision algorithms ... combined with visualization of only the diagnostically most ...
(Date:8/21/2014)... COLD SPRING, N.Y. , Aug. 21, 2014 ... today the launch of their Nutraceutical "TELO-20 for ... first and only Telomere-lengthening supplement in the world ... the ends of every chromosome in the body. ... the world,s leading experts in Telomere Science and ...
Breaking Biology Technology:Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 2Nerium International Joins Television’s Biggest Stars at Backstage Creations Giving Suite at the 66th Primetime Emmy Awards 3A novel 'man and machine' decision support system makes malaria diagnostics more effective 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 2Telomere Biosciences Announces: TELO-20 for Dogs, the World's First Telomere-Lengthening Supplement for Dogs, to Promote Healthy Aging and Longevity 3
... , , , ... SHP, Nasdaq: SHPGY ), the global specialty biopharmaceutical ... care of adults with Attention-Deficit/Hyperactivity Disorder (ADHD), a psychiatric behavioral ... country.* The first initiative, "RoADHD Trip," a multi-city self ...
... Aug. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ... letter from the Listing Qualifications Department of The NASDAQ ... with Listing Rule 5550(a)(2). , We plan to request ... Panel") to review the NASDAQ,s determination of the continued ...
... Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) ... therapy and oncology, today reported Phase 3 results for ... trial Z-041 in benign prostatic hyperplasia (BPH), with its ... on March 6, 2009, sanofi-aventis U.S. LLC entered into ...
Cached Biology Technology:Shire Initiates Two Adult ADHD Outreach Programs 2Shire Initiates Two Adult ADHD Outreach Programs 3Shire Initiates Two Adult ADHD Outreach Programs 4Vasogen Receives NASDAQ Notification Related to Minimum Bid Price 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 4AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 5AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 6AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia 7
(Date:8/21/2014)... they are the ultimate source of all organic matter ... on algae, too, to suck up climate-warming carbon dioxide ... of the ocean. Now, by using a combination of ... that viruses infecting those algae are driving the life-and-death ... stays essentially the same, and this has important implications ...
(Date:8/21/2014)... In a finding that has implications for life in ... in the solar system, LSU Associate Professor of Biological ... National Science Foundation, or NSF, this week published a ... lake that lies 800 meters (2600 feet) beneath the ... microbial ecosystems.", Given that more than 400 subglacial lakes ...
(Date:8/21/2014)... connectors, designed by an international standards process, will be ... to an invited review published in the OnlineFirst version ... ), the official journal of the American Society for ... greatly reduce the occurrence of misconnection that can be ... which are used to join medical devices, components, and ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4New feeding tube connectors will improve patient safety 2
... NARRAGANSETT, R.I. August 30, 2010 ... at the University of Rhode Island Graduate School ... Science Foundation (NSF) RAPID Response grant through the ... $199,909 NSF grant, Improving Communication of Oil Spill ...
... Undergrads often take communication courses unrelated to their major ... teamed up with the Library and English Departments to ... and understand literature searchers and incorporate them into papers ... and Gail R. Nonnecke, Iowa State University faculty from ...
... diseases are hereditary. But despite significant progress in genome ... The discovery of the underlying genetic defect is, however, ... of innovative approaches to their treatment. Scientists at the ... of Medical Genetics at the Charit Universittsmedizin - Berlin ...
Cached Biology News:Metcalf Institute wins NSF grant to help journalism and communication of oil spill research 2Teaching communication and information literacy skills 2All genes in 1 go 2
... The SlowFade Light Antifade Kit is ... photobleaching seen with fluorescent dyes. This formulation ... fluorescein AMCA and Cascade Blue fluorophores that ... (S-2828). This kit is available with the ...
Human Xg Affinity Purified Polyclonal Ab Keywords: Xg glycoprotein, hereditary hemorrhagic telangiectasia Protein Family: ...
in vitro Translation, Accessory Products...
...
Biology Products: